Nanophage Technologies Limited

Founded in 2021 in Palmerston North, New Zealand, by Jasna Rakonjac, Nanophage Technologies Ltd focuses on innovative nanotechnology solutions. The company has successfully completed 1 deal, with the latest deal occurring on March 18, 2026, where it raised USD 2. 5 mn in venture funding. As of May 2026, Paul Smith is the CEO of the company.

Nanophage Technologies specializes in the development of innovative nanorod technology designed to enhance detection molecules, thereby increasing their brightness. This proprietary technology serves a critical role in various applications, including diagnostics, biosensing, and medical imaging, providing users with enhanced sensitivity and performance in detecting specific biological markers. The company has focused on commercializing this technology for use in sectors such as healthcare and scientific research, targeting laboratories and research institutions across North America and Europe. By improving the performance of detection systems, Nanophage Technologies aims to address challenges in early disease diagnosis and monitoring, particularly in complex biological environments.

Their products cater to a diverse clientele, including diagnostic companies, research laboratories, and healthcare professionals, ensuring a broad impact across multiple market segments. Nanophage Technologies generates revenue primarily through a business-to-business (B2B) model, offering its advanced nanorod products to laboratories and research institutions. The transactions typically involve direct sales agreements or partnerships, where clients procure bulk quantities of nanorod technology for integration into their diagnostic systems and research applications. These partnerships often come with tailored pricing arrangements based on the volume of products ordered, allowing for scalability and accommodating varying client needs.

Flagship offerings may include specific nanorod formulations that have been optimized for particular applications, with pricing based on product specifications and required performance characteristics. In March 2026, Nanophage Technologies Ltd raised USD 2. 5 mn in venture funding which aims to move from lab-scale production to commercial manufacturing, secure revenue contracts and launch our first sensitivity-boosting research kit.